{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:06:56Z","timestamp":1751983616726},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":74,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2001,10,30]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. The aim of the present study was to determine the effects of the metalloendopeptidase (EP) 24.15 and 24.16 inhibitor <jats:italic>N<\/jats:italic>\u2010[1\u2010(<jats:sc>R<\/jats:sc>,<jats:sc>S<\/jats:sc>)\u2010carboxy\u20103\u2010phenylpropyl]\u2010Ala\u2010Aib\u2010Tyr\u2010<jats:italic>p<\/jats:italic>\u2010aminobenzoate (JA\u20102) on haemodynamics and renal function in conscious rabbits with two\u2010kidney, two\u2010wrapped hypertension. We have also examined the role of endogenous bradykinin in the maintenance phase of this form of renovascular hypertension and whether inhibition of bradykinin degradation contributes to any potential effects of JA\u20102.<\/jats:p><jats:p>2. In two preliminary operations, rabbits were equipped with transit\u2010time ultrasound flow probes for measuring cardiac output (CO) and renal blood flow (RBF) and had both kidneys wrapped in cellophane. Starting 4 weeks after the last operation, rabbits underwent four studies (3\u20135 days apart), during which they were treated with combinations of the bradykinin B<jats:sub>2<\/jats:sub> receptor antagonist icatibant or its vehicle (1 mL\/kg bodyweight 0.9% w\/v NaCl) and JA\u20102 or its vehicle (1 mL\/kg of a 5% w\/v 2\u2010hydroxypropyl\u2010<jats:bold>\u03b2<\/jats:bold>\u2010cyclodextrin, 2.5% v\/v dimethylsulphoxide solution). Renal function was monitored using standard renal clearance methods.<\/jats:p><jats:p>3. Icatibant (10 <jats:bold>\u03bc<\/jats:bold>g\/kg) had no significant effects on systemic haemodynamic variables (mean arterial pressure, heart rate or CO), renal haemodynamic variables (RBF or glomerular filtration rate), urine flow or sodium excretion. At 5 mg\/kg plus 3 mg\/kg per h, JA\u20102 also did not affect any of these variables, either after icatibant vehicle treatment or after icatibant treatment.<\/jats:p><jats:p>4. Our data do not support major roles for endogenous bradykinin or bradykinin degradation by EP 24.15\/24.16 in the control of systemic and renal haemodynamics or renal excretory function in two\u2010kidney, two\u2010wrapped hypertension in rabbits.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2001.03532.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:07:54Z","timestamp":1047380874000},"page":"836-841","source":"Crossref","is-referenced-by-count":5,"title":["Metalloendopeptidases EC 3.4.24.15 and EC 3.4.24.16 And Bradykinin B<sub>2<\/sub> Receptors Do Not Play Important Roles In Renal Wrap Hypertension In Rabbits"],"prefix":"10.1111","volume":"28","author":[{"given":"M Ursula","family":"Norman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Ian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate M","family":"Denton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger G","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","unstructured":"SkidgelRA.Bradykinin\u2010degrading enzymes: Structure function distribution and potential roles in cardiovascular pharmacology.J. Cardiovasc. Pharmacol.1992;20(Suppl. 9): S4\u20139.","DOI":"10.1097\/00005344-199200209-00003"},{"key":"e_1_2_6_3_2","first-page":"25","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin\u2010converting enzyme inhibitors.","volume":"47","author":"Linz W","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2610951"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8941"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-116-4-1418"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb11021.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1987.tb13160.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1523\/JNEUROSCI.16-16-05049.1996","article-title":"Distinct properties of neuronal and astrocytic endopeptidase 3.4.24.16: A study on differentiation, subcellular distribution, and secretion processes.","volume":"16","author":"Vincent B","year":"1996","journal-title":"J. Neurosci."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.18.3.360"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(92)90053-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(93)90185-J"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2940681"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15533.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13332.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","unstructured":"ShrimptonCN AbbenanteG LewRA SmithI.Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15.Biochem. J.2000;345: 351\u20136.","DOI":"10.1042\/bj3450351"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","unstructured":"SmithAI LewRA ShrimptonCN EvansRG AbbenanteG.A novel stable inhibitor of endopeptidases EC 3.4.24.15 and 3.4.24.16 potentiates bradykinin\u2010induced hypotension.Hypertension2000;35: 626\u201330.","DOI":"10.1161\/01.HYP.35.2.626"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15995.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198312000-00005"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.7.6.893"},{"key":"e_1_2_6_21_2","first-page":"457","article-title":"Alterations in responses to bradykinin, angiotensin I, and angiotensin II during the induction phase of one\u2010kidney, one\u2010wrapped hypertension and associated arterial disease in rabbits.","volume":"98","author":"Campbell WG","year":"1980","journal-title":"Am. J. Pathol."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.5.1237"},{"key":"e_1_2_6_23_2","first-page":"F626","article-title":"Glomerular B2\u2010 kinin\u2010binding sites in two\u2010kidney, one\u2010clip hypertensive rats.","volume":"260","author":"Emond C","year":"1991","journal-title":"Am. J. Physiol."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004240051139"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12249.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.3.303"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.2.6.794"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","unstructured":"CampbellDJ.Towards understanding the kallikrein\u2013kinin system: Insights from measurement of kinin peptides.Braz. J. Med. Biol. Res.2000;33: 665\u201377.","DOI":"10.1590\/S0100-879X2000000600008"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0162-3109(99)00089-2"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","unstructured":"TornelJ MadridMI Garcia\u2010SalomM WirthKJ FenoyFJ.Role of kinins in the control of renal papillary blood flow pressure natriuresis and arterial pressure.Circ. Res.2000;86: 589\u201395.","DOI":"10.1161\/01.RES.86.5.589"},{"key":"e_1_2_6_31_2","first-page":"1339","article-title":"Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.","volume":"265","author":"Pham I","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.23.1_Suppl.I235"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00402a015"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2001.03532.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2001.03532.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:58:39Z","timestamp":1697522319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2001.03532.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,30]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,30]]}},"alternative-id":["10.1046\/j.1440-1681.2001.03532.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2001.03532.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,30]]}}}